Title |
Efficacy, Safety, and Tolerability of Pantoprazole Magnesium in the Treatment of Reflux Symptoms in Patients with Gastroesophageal Reflux Disease (GERD): A Prospective, Multicenter, Post-Marketing Observational Study
|
---|---|
Published in |
Clinical Drug Investigation, December 2013
|
DOI | 10.1007/s40261-013-0135-4 |
Pubmed ID | |
Authors |
José María Remes-Troche, Sergio Sobrino-Cossío, Julio César Soto-Pérez, Oscar Teramoto-Matsubara, Miguel Morales-Arámbula, Antonio Orozco-Gamiz, José Luis Tamayo de la Cuesta, Gualberto Mateos |
Abstract |
To improve proton pump inhibitor effects, pharmacological modifications have been developed such as the use of enantiomer molecules (e.g., S-omeprazole, S-pantoprazole, or dexlansoprazole), or addition of NaHCO3 (for an immediate release) or magnesium (with a lower absorption for a more sustained effect). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 38 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 7 | 18% |
Other | 6 | 16% |
Researcher | 5 | 13% |
Student > Ph. D. Student | 4 | 11% |
Student > Master | 3 | 8% |
Other | 7 | 18% |
Unknown | 6 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 39% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 11% |
Nursing and Health Professions | 3 | 8% |
Unspecified | 3 | 8% |
Psychology | 2 | 5% |
Other | 4 | 11% |
Unknown | 7 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 August 2023.
All research outputs
#3,402,534
of 24,244,537 outputs
Outputs from Clinical Drug Investigation
#90
of 999 outputs
Outputs of similar age
#39,751
of 315,744 outputs
Outputs of similar age from Clinical Drug Investigation
#1
of 10 outputs
Altmetric has tracked 24,244,537 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 999 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,744 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them